Reminder: Merck to Hold 2011 Full-Year and Fourth-Quarter Sales and Earnings Conference Call on February 2

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- As previously announced on Oct. 31, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its 2011 full-year and fourth-quarter sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 2. During the call, Kenneth C. Frazier, chairman and chief executive officer; Adam H. Schechter, president, Global Human Health; and Peter N. Kellogg, executive vice president and chief financial officer, will provide an overview of Merck’s business and financial performance.

Investors are invited to a live audio webcast of Merck's fourth-quarter earnings conference call on Feb. 2 at 8:00 a.m. EST by visiting Merck's Web site, www.merck.com/investors/events-and-presentations/home.html. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782. Journalists are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917. A replay of the call will be available starting Feb. 2 at 11 a.m. EST for approximately one week. To listen to the replay, dial (404) 537-3406 or (855) 859-2056 and enter ID No. 23636062.

About Merck

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.



CONTACT:

Merck
Media:
Ron Rogers, 908-423-6449
or
Investors:
Carol Ferguson, 908-423-4465

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.